EDX Medical Group participating in “The Pub Test” Investor Evening

EDX Medical Group plc

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced its participation in “The Pub Test” Investor Evening. This event is co-hosted by the Aquis Exchange and InvestorHub and will take place on Wednesday, 17th July 2024 at Samuel Pepys, Stew Ln, London EC4V 3PT, starting at 6:00 PM.

The Company’s CEO, Dr Mike Hudson, will engage in a conversation designed especially for private investors. This informal setting offers an opportunity for attendees to interact directly with company executives, ask questions, and network with fellow investors.

Commenting on the event, EDX Medical Group Dr Mike Hudson, said:

“We look forward to meeting and engaging with interested parties, shareholders, potential shareholders, and stakeholders, share our vision and answer any questions investors may have.”

All attendees will have the chance to network over drinks and a buffet.

To register for the event, please use the following link: https://events.humanitix.com/the-pub-test-or-london-july-4-2024

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

EDX Medical Group deploys rapid pneumonia test at Addenbrooke’s ICU

EDX Medical Group has said its rapid pneumonia test is now in NHS clinical practice and has benefited patients at Addenbrooke's Hospital.

Professor Sir Chris Evans outlines EDX Medical’s new workplace health screening service

EDX Medical’s Chief Scientific Officer discusses the service’s on-site testing model, competitive advantages, employer demand and potential to generate more than £2 million this financial year.

EDX Medical launches BC95 bowel cancer testing service in the UK

EDX Medical Group has launched full UK availability of its BC95 bowel cancer biomarker testing service, combining early detection, hereditary risk analysis and a faecal haemoglobin reference test. The service reports sensitivity above 95% across all cancer stages and is designed to improve early diagnosis of colorectal cancer, which affects more than 46,000 people annually in the UK.

EDX Medical Group Targets More Than £2 Million From New Employee Health Screening Service (video)

Chief Scientific Officer Sir Chris Evans explains how its on-site testing model, multi-biomarker panels and personalised reports could help employers identify health risks earlier while reducing disruption and absenteeism.

EDX Medical builds scale through Scottish Prostate Cancer Testing programme

EDX Medical is expanding its role in a 25,000-participant Scottish programme testing a more targeted approach to prostate cancer detection.

EDX Medical builds momentum around precision cancer testing

EDX Medical is advancing precision cancer diagnostics through large-scale prostate testing in Scotland, AIM market access and a wider commercial rollout of disease detection products.

Search